Condition

ESCC (1)

Extensive Stage Small Cell Lung Cancer (1)

Ionizing Radiation Exposure (1)

NSCLC (1)

Ovarian Cancer (1)

Quality Improvement (1)

Solid Tumors (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Unknown status (1)

Phase

n/a (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Astellas Pharma Global Development, Inc. (1)

University Hospital Southampton NHS Foundation Trust (1)

University of California, San Francisco (1)

Intervention

asp0739 (1)

in-person meeting (1)

ipilimumab (1)

multi-component intervention (1)

pembrolizumab (1)

simple audit report (1)

Study Documents

Intervention Type

biological (1)

drug (1)

other (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

ASP0739

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Ovarian Cancer, NSCLC, ESCC Trial in United States (ASP0739, Pembrolizumab)

Active, not recruiting

Ovarian Cancer
+3 more

ASP0739
Pembrolizumab

Duarte, California
+6 more

Jan 21, 2023

Ionizing Radiation Exposure, Quality Improvement Trial (Simple Audit Report, Multi-Component Intervention, In-Person Meeting)

Unknown status

Ionizing Radiation Exposure
Quality Improvement

Simple Audit Report
+2 more

(no location specified)

Mar 23, 2020

Extensive Stage Small Cell Lung Cancer Trial in United Kingdom (Ipilimumab)

Completed

Extensive Stage Small Cell Lung Cancer

Ipilimumab

Bournemouth, United Kingdom
+6 more

Apr 13, 2016